A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease
Avicenna · 2014
DOI: 10.5339/avi.2014.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Avicenna, 2014. Verfasst von Andrea Lynn Cartwright und 1 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Current clinical recommendations for patients with stable coronary artery disease (CAD) and those post-acute coronary syndromes (ACS) suggest initiation of patients on dual antiplatelet therapy, an angiotensin-converting enzyme (ACE) inhibitor, a beta-blocker and an HMG-CoA reductase inhibitor prior to hospital discharge. Commonly, this drug regimen is continued indefinitely. More recently, however, emerging evidence suggests that long-term therapy with beta-blockers may in fact be of no benefit to patients with stable CAD. This evidence-based review will summarize the current practice recommendations, as well as provide a critical analysis of available literature regarding beta-blockers in stable CAD. Both efficacy and safety will be considered and implications for current clinical practice will be discussed.
Zitieren
APA
Cartwright, A. L., & Wilby, K. J. (2014). A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease. Avicenna. https://doi.org/10.5339/avi.2014.4
Vancouver
Cartwright AL, Wilby KJ. A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease. Avicenna. 2014. doi:10.5339/avi.2014.4
BibTeX
@article{Cartwright2014,
author = {Cartwright, Andrea Lynn and Wilby, Kyle John},
title = {A critical evidence-based summary of the use of beta-blockers in stable coronary artery disease},
journal = {Avicenna},
year = {2014},
doi = {10.5339/avi.2014.4}
}
EUVIMED